These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31190745)

  • 21. Virologic and immunologic effectiveness of tipranavir/ritonavir (TPV/r)- versus darunavir/ritonavir (DRV/r)-based regimens in clinical practice.
    Antoniou T; Raboud JM; Diong C; Su D; Dewhurst N; Buckley V; Kovacs C; Rachlis A; Brunetta J; Smith G; Gough K; Fletcher D; Loutfy MR
    J Int Assoc Physicians AIDS Care (Chic); 2010; 9(6):382-9. PubMed ID: 21138833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short Communication: Efficacy and Safety of Treatment Simplification to Lopinavir/Ritonavir or Darunavir/Ritonavir Monotherapy: A Randomized Clinical Trial.
    Santos JR; Llibre JM; Bravo I; García-Rosado D; Cañadas MP; Pérez-Álvarez N; Paredes R; Clotet B; Moltó J
    AIDS Res Hum Retroviruses; 2016 May; 32(5):452-5. PubMed ID: 26781004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.
    De Wit S; Florence E; Vandekerckhove L; Vandercam B; Goffard JC; Van Wijngaerden E; Moutschen M; Demeester R; Thilakarathne P; Piryns H;
    Acta Clin Belg; 2018 Oct; 73(5):341-347. PubMed ID: 29623779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PEPDar: A randomized prospective noninferiority study of ritonavir-boosted darunavir for HIV post-exposure prophylaxis.
    Fätkenheuer G; Jessen H; Stoehr A; Jung N; Jessen AB; Kümmerle T; Berger M; Bogner JR; Spinner CD; Stephan C; Degen O; Vogelmann R; Spornraft-Ragaller P; Schnaitmann E; Jensen B; Ulmer A; Kittner JM; Härter G; Malfertheiner P; Rockstroh J; Knecht G; Scholten S; Harrer T; Kern WV; Salzberger B; Schürmann D; Ranneberg B
    HIV Med; 2016 Jun; 17(6):453-9. PubMed ID: 27166295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and durability in a cohort of HIV-1 positive patients treated with once and twice daily darunavir-based therapy (SCOLTA Project).
    Menzaghi B; Ricci E; Carenzi L; Parruti G; Orofino G; Guastavigna M; Madeddu G; Maggi P; Di Biagio A; Corsi P; Penco G; De Socio G; Martinelli C; Vichi F; Celesia BM; Franzetti M; Grosso C; Molteni C; Bonfanti P; Quirino T
    Biomed Pharmacother; 2013 May; 67(4):293-8. PubMed ID: 23433852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
    Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain.
    Pernas B; Grandal M; Tabernilla A; Cid P; Pértega S; Castro-Iglesias Á; Mena Á; Margusino L; Pedreira JD; Poveda E
    J Med Virol; 2016 Dec; 88(12):2125-2131. PubMed ID: 27218208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
    Dierynck I; De Meyer S; Lathouwers E; Vanden Abeele C; Van De Casteele T; Spinosa-Guzman S; de Béthune MP; Picchio G
    Antivir Ther; 2010; 15(8):1161-9. PubMed ID: 21149923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Darunavir as first-line therapy. The TITAN study].
    Curran A; Ribera Pascuet E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():14-22. PubMed ID: 19195455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
    Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
    Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
    Huhn GD; Sigman A; Livak B
    Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Week 96 efficacy and safety of darunavir/ritonavir monotherapy vs. darunavir/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial.
    Girard PM; Antinori A; Arribas JR; Ripamonti D; Bicer C; Netzle-Sveine B; Hadacek B; Moecklinghoff C
    HIV Med; 2017 Jan; 18(1):5-12. PubMed ID: 27279571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of Cardiovascular Disease Risk in HIV-1-Infected Patients Treated with Darunavir.
    Opsomer M; Dimitrova D; Verspeelt J; Purrington A; Mehbob A; Chavers S; Pai H; Vanveggel S; Luo D; Brown K; Moecklinghoff C; Nettles RE; Boven K
    Drugs R D; 2018 Sep; 18(3):199-210. PubMed ID: 29992490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of unboosted darunavir in the setting of ritonavir intolerance: three case reports.
    Smith K; Gomes D; Nixon D; Fulco PP
    Int J Clin Pharmacol Ther; 2016 Jan; 54(1):52-7. PubMed ID: 26636419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
    Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.
    Delaugerre C; Pavie J; Palmer P; Ghosn J; Blanche S; Roudiere L; Dominguez S; Mortier E; Molina JM; de Truchis P
    AIDS; 2008 Sep; 22(14):1809-13. PubMed ID: 18690163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.